Ajai Chari, MD; C. Ola Landgren, MD, PhD; Pei Lin, MD; and Nina Shah, MD, explain the clinical implications of achieving MRD negativity in patients who have high-risk multiple myeloma and remark on the outcomes of the IFM/DFCI meta-analysis reported at the 2017 American Society of Hematology (ASH) Annual Meeting.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
